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We sought to compare the tumor proﬁles of brain metastases from common cancers with those of primary tumors and extracranial
metastases in order to identify potential targets and prioritize rational treatment strategies. Tumor samples were collected from
both the primary and metastatic sites of nonsmall cell lung cancer, breast cancer and melanoma from patients in locations
worldwide, and these were submitted to Caris Life Sciences for tumor multiplatform analysis, including gene sequencing (Sanger
and next-generation sequencing with a targeted 47-gene panel), protein expression (assayed by immunohistochemistry) and gene
ampliﬁcation (assayed by in situ hybridization). The data analysis considered differential protein expression, gene ampliﬁcation
and mutations among brain metastases, extracranial metastases and primary tumors. The analyzed population included: 16,999
unmatched primary tumor and/or metastasis samples: 8,178 nonsmall cell lung cancers (5,098 primaries; 2,787 systemic
metastases; 293 brain metastases), 7,064 breast cancers (3,496 primaries; 3,469 systemic metastases; 99 brain metastases) and
1,757melanomas (660 primaries; 996 systemic metastases; 101 brain metastases). TOP2A expression was increased in brain
metastases from all 3 cancers, and brain metastases overexpressed multiple proteins clustering around functions critical to DNA
synthesis and repair and implicated in chemotherapy resistance, including RRM1, TS, ERCC1 and TOPO1. cMET was overexpressed
in melanoma brain metastases relative to primary skin specimens. Brain metastasis patients may particularly beneﬁt from
therapeutic targeting of enzymes associated with DNA synthesis, replication and/or repair.
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Introduction
Metastasis is the most common source of tumors in the brain, with
lung cancer, breast cancer and melanoma being the most common
solid tumors spreading to the central nervous system (CNS).1
Overall, it is estimated that 9–17% of cancer patients will develop
brain metastases during the course of their disease and that
approximately half will die within 3–27 months from initial diag-
nosis of CNS involvement.1–3 The reported median survival times
for NSCLC, breast cancer and melanoma after the diagnosis of
brain metastasis are 7.8 months, 15 months and 7–7.9 months,
respectively.4–6 The poor survival associated with brain metastases
is largely attributed to our incomplete understanding of the molec-
ular mechanisms governing organotropism and the brain itself
being a known sanctuary site. Additionally, most systemic thera-
peutics are not capable of crossing the blood–brain barrier (BBB).
The need for additional treatment options is urgent; more than
100,000 patients per year develop brain metastases in the United
States, and the current treatment cost exceeds 3 billion dollars.7
Current treatment options include surgical resection and various
forms of irradiation, but these have only a modest impact on over-
all outcome and carry variable risks of neurological morbidity.
There are no effective systemic therapies speciﬁcally approved for
brain metastases. Unfortunately, once CNS involvement is present,
effective treatment options are limited and the prognosis is dismal.
These issues are pressing, as the incidence of brain metastasis may
be increasing due to longer patient survival owing to newer sys-
temic therapies that control extracranial disease, along with more
frequent magnetic resonance imaging surveillance.3,5
There has been a surge in clinical trials guided by genomics in
order to better match patients with effective, targeted cancer treat-
ments.8 The development of CNS metastases often results in
exclusion of patients from clinical trials,9 particularly phase I trials
of many novel therapeutics, mainly due to the known poor prog-
nosis and limited efﬁcacy of systemic therapy for these patients
historically. Detailed molecular analyses of metastases across
pathologies may help identify new therapeutic targets that can
beneﬁt these patients. Thus, we performed a multiplatform analy-
sis of a large cohort of brain and systemic metastasis samples col-
lected from the cancers most commonly predisposed to produce
brain metastases in order to identify potentially actionable targets.
Materials and Methods
Study population
From 2009 to 2015, tumors collected from both the primary and
metastatic sites of nonsmall cell lung cancer (NSCLC), breast
cancer and melanoma from patients in locations worldwide were
submitted to Caris Life Sciences for tumor multiplatform analysis.
A total of 8,178 NSCLC (5,098 primaries; 2,787 systemic metasta-
ses; 293 brain metastases), 7,064 breast cancer (3,496 primaries;
3,469 systemic metastases; 99 brain metastases) and 1,757 mela-
noma (660 primaries; 996 systemic metastases; 101 brain metasta-
ses) samples (primary and metastases not matched to the same
patient) were retrospectively analyzed. Our study is exempt per
policy 45 CFR 46.101 (b); the data analyzed is from an existing
commercial repository and subject information is de-identiﬁed.
Immunohistochemistry
All analysis by immunohistochemistry (IHC) was performed
on full slides of formalin-ﬁxed parafﬁn-embedded (FFPE)
tumor specimens. Following the requirements of the Clinical
Laboratory Improvement Amendments (CLIA)/Compliance
Assistance Ofﬁce (CAO) and International Organization for
Standardization (ISO), staining conditions were performed
per the manufacturer’s instructions using automated staining
techniques and were optimized and validated. The results
were evaluated and conﬁrmed by independent board-certiﬁed
pathologists. Immunohistochemical scoring was based on
staining percentage (0–100%) and intensity (0 = no staining; 1
+ = weak staining; 2+ = moderate staining; 3+ = strong stain-
ing). Representative staining photos are shown in Supporting
Information Figure S1. Results were categorized as positive or
negative by deﬁned thresholds speciﬁc to each marker based on
published clinical literature that associates biomarker status
with patient responses to therapeutic agents. Supporting Infor-
mation Table S1 shows the thresholds for positive and negative
categorization. Tumor cells were evaluated for proteins of inter-
est. Analyzed proteins and antibodies used are listed in Sup-
porting Information Table S2. PD-L1 staining results are
speciﬁc for membranous staining, and PD-1 expression was
evaluated by analysis of tumor-inﬁltrating lymphocytes as pre-
viously described.10 The expression of PD-L1 was analyzed with
B7-H1 antibody (R&D systems) using automated immunohis-
tochemical methods. Dilutions and conditions were based on
package insert instructions, were optimized and validated and
met the standards and requirements of the CLO/CAO and ISO.
In situ hybridization (ISH)
Gene ampliﬁcation was assessed using ﬂuorescence in situ
hybridization (FISH) for EGFR (EGFR/CEP7 probe) and
TOP2A (TOP2A/CEP17 probe). Both FISH and chromogenic
What’s new?
Brain metastases are difﬁcult to treat and generally lethal. Here, the authors sought clues to possible treatment targets by
comparing the molecular characteristics of lung, breast, and skin cancers with those of brain metastases. They analyzed DNA
sequence, protein expression, and gene ampliﬁcation on over 17,000 samples, the largest metastases cohort ever studied.
They found that the enzyme TOP2A, involved in DNA transcription, was enriched in the metastatic cells relative to the primary
tumor cells. Other enzymes, involved in DNA synthesis, repair, and replication were also overexpressed in metastases, and
could potentially be useful therapeutic targets.
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in situ hybridization (CISH) were used to detect gene ampliﬁ-
cation of cMET (cMET/CEP7 probe and Ventana kit) and
Her2 (HER-2/CEP17 probe and INFORM HER-2 Dual ISH
DNA Probe Cocktail). EGFR ampliﬁcation was deﬁned by the
presence of an EGFR/CEP7 ratio of ≥2, or ≥ 15 EGFR copies
per cell in ≥10% of analyzed cells. A ratio of TOP2:CEP
17 ≥ 2.0 and an HER-2/CEP17 ratio ≥ 2 was considered
ampliﬁed; cMET was considered ampliﬁed if ≥5 copies per
tumor cell were detected on average.
Mutational analysis
Using the Illumina MiSeq platform, sequencing was performed
on genomic tumor DNA isolated from FFPE tumor tissue
(germline DNA was not sequenced). Reference genome used
was hg19 from the UCSC Genome Browser database (http://
hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/). Speciﬁc
regions of 47 genes (panel of pan-cancer genes of interest related
to cancer genomics based on current literature) were ampliﬁed
using the customized Illumina TruSeq Amplicon Cancer Hot-
spot panel.11 All variants reported were detected with >99% con-
ﬁdence based on the mutation frequency present. Mutations
including PTEN, TP53 and BRAF and were evaluated by Next-
generation sequencing (NGS; Illumina MiSeq platform)
(Supporting Information Table S3). The average depth of cover-
age of the hotspot panel was >1,500x and the tumor content
requirement is ≥20%. This test has a sensitivity to detect as low
as a 10% population of cells containing a mutation in a
sequenced amplicon. All variants reported were detected with
>99% conﬁdence based on the frequency of the mutation pre-
sent and the amplicon coverage. Note that as this is a commer-
cial repository, mutational testing on individual samples was
performed at the discretion of the ordering physician. Hence,
not all samples were tested for all mutations. Additionally, a
cohort of patients was proﬁled prior to the availability of NGS.
Statistical analysis
Comparisons of biomarker proﬁles, including protein expres-
sion (IHC), gene ampliﬁcation (CISH/FISH) and mutation
(Sanger sequencing and NGS) between tumor sites were per-
formed using Fisher’s exact test. To adjust for the multiple
testing and limit the risk of false positive results, p values
resulting from the Fisher’s exact test were corrected using the
Benjamini-Hochberg procedure.12 All reported p values are
two sided and corrected for multiple comparison. P values of
less than 0.05 were declared as statistically signiﬁcant. All ana-
lyses were performed with statistical software R v3.3.1.
Results
Study population
Patient characteristics, number of tumor specimens and distri-
bution of systemic metastases (extracranial) are shown in
Table 1 and Supporting Information Table S4. A total of
16,999 specimens were included for analysis; 9,252 primary
lesions, 493 brain metastases and 7,252 systemic (extra-cranial
metastases). The majority of extracranial specimens were
obtained from the lymph nodes. Sex was equally dichotomized
among the NSCLC patients, breast cancer cases were mostly
restricted to females and males were overrepresented in
melanoma. Overall, the breast cancer patient population was
younger than the NSCLC and melanoma cohorts.
TOP2A expression is a high frequency target in brain
metastases relative to primary tumors
Using a CLIA-compliant cancer protein panel, differential
expression was proﬁled in NSCLC, breast cancer and mela-
noma specimens (Fig. 1, Supporting Information Table S5).
Across pathologies, TOP2A, which controls and alters the
topologic states of DNA during transcription, was the protein
expressed more frequently in the brain metastases relative to
the primary tumors most consistently (NSCLC: 74.5% versus
55%, p < 0.0001; breast cancer: 78.8% versus 50.1%, p = 0.0001;
melanoma: 76.4% versus 45.8%, p = 0.0007) (Fig. 2). Levels of
two other enzymes involved in DNA synthesis and chemoresis-
tance, RRM1 and TS, were also increased in NSCLC brain
metastases relative to the primary (31.8% versus 20.9%,
p = 0.0049; and 34.9% versus 21.5%, p = 0.0006, respectively),
but this was only a trend for increased expression detected in
breast cancer and melanoma brain metastases. Other DNA topoi-
somerases and enzymes essential for DNA replication/repair such
as TOPO1 (77.9% versus 63.4%, p = 0.0357) and ERCC1 (61.8%
versus 42.1%, p = 0.0199) were also more frequently expressed in
breast cancer brain metastases. Her2/Neu expression was more
common in breast cancer brain metastases (23.3%) compared
with primary specimens (11.6%) (p = 0.0227), whereas the fre-
quency of expression of all hormonal receptors (AR: 20.5% versus
51.3%, p < 0.0001; ER: 34.4% versus 54.1%, p = 0.0049; PR: 25.3%
versus 43.6%, p = 0.008) was signiﬁcantly reduced in brain metas-
tases relative to the primary tumor. Melanoma brain metastases
exhibited increased cMET expression frequency relative to the
primary (36.4% versus 7.9%, p = 0.0003) but decreased TUBB3
expression (38.2% versus 76.2%, p = 0.0007).
Her2/Neu protein expression is more frequent in breast
cancer brain metastases than in systemic metastases
To ascertain whether the differences in protein expression
were a function of the process of metastasis in general or were
more speciﬁc to brain metastasis, we next compared differen-
tial protein expression in brain and systemic metastases across
tumor pathologies (Fig. 1, Supporting Information Table S5).
Her2/Neu expression was signiﬁcantly higher in breast brain
metastases (23.3%) than in systemic metastases (9.9%)
(p = 0.0044). Moreover, all hormone receptors were expressed
less frequently in breast cancer brain metastases (AR,
p < 0.0001; ER, p = 0.0001 and PR, p = 0.019)—similar to the
comparison with primary sites. Systemic breast metastases
showed an increased frequency of PTEN (52.7% versus 34%,
p = 0.0049) and MGMT (68% versus 47.3%, p = 0.0011)
relative to brain metastases (Fig. 2).
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Breast cancer brain metastasis demonstrated enrichment of
Her2 and EGFR gene ampliﬁcations relative to systemic
metastases and primary lesions
Gene ampliﬁcation results for NSCLC, breast cancer and mel-
anoma are presented in Table 2. A total of 2,888 breast cancer
specimens were evaluated for Her2 ampliﬁcation using FISH
(2,808 breast primaries), with 28.8% (n = 80) of brain metas-
tases displaying Her2 ampliﬁcation relative to 15.3% (n = 430)
of the primary specimens (p = 0.0227). Her2 ampliﬁcation
was also signiﬁcantly higher in breast cancer brain metastases
than in systemic metastases (13.1%) (p = 0.004), consistent
with HER2-expressing cells having a greater propensity to
spread to the brain.13,14 Furthermore, EGFR ampliﬁcation was
more common in breast cancer brain metastases (31.1%) than
in primaries (14.1%; p = 0.0341). Similarly, EFGR ampliﬁca-
tion was higher in brain metastases than in systemic lesions
(14.2%; p = 0.0333). EGFR was also ampliﬁed in melanoma
brain metastases (50%) and NSCLC brain metastases (36.3%)
relative to the primary cancers (6.1% and 28%, respectively),
but these differences were not statistically signiﬁcant.
Minimal differences in mutational frequency between
metastases and primary lesions
DNA sequencing data were analyzed for a panel of 47 well-
annotated pan-cancer genes (listed in Supporting Information
Table S6). In most cases, the most common mutations were
found in both the primary cancers and brain metastases with
Table 1. Summary of characteristics of patients with brain and systemic metastases from non-small cell lung cancer, breast cancer and
melanoma
Histology Specimen site Number of samples Age (median) Sex (% female)
Nonsmall cell lung cancer Brain 293 61 54.9
Lung 5,098 68 52
Systemic Metastases 2,787 65 51
Breast cancer Brain 99 51 100
Breast 3,496 55 99.3
Systemic Metastases 3,469 57 99
Melanoma Brain 101 62 35.3
Skin/(Primary) 660 66 35.6
Systemic Metastases 996 64 62.5
Summary Primary 9,254 63 69
Brain 493 59 70
Systemic Metastases 7,252 61 71.8
Total 16,999 62 70
Figure 1. Differential protein expression by tumor pathology (NSCLC, breast cancer and melanoma). Figure displaying changes in expression
of 20 cancer-related proteins in primary lesions, brain and systemic metastases. Numbers in the cells indicate rounded up fractions.
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similar frequencies. However, there were some notable excep-
tions in breast cancer. For example, ABL1 mutations were
more frequent in breast cancer brain metastases (11.1%; 2/18)
than in primary breast cancers (0.4%; 3/822) (p = 0.0319) and
PIK3CA mutations were more frequent in breast systemic
metastases (30.3%; 415/1,370) than in brain metastases
(10.3%; 4/39) (p = 0.0426) (Fig. 3; Supporting Information
Table S7).
Discussion
Multiplatform analysis was performed on approximately
17,000 primary and metastatic cancers, which is the largest
cohort described in the literature, in order to reveal potential
therapeutic targets. We observed a signiﬁcant association
between TOP2A protein expression and brain metastases.
TOP2A is a critical enzyme in DNA transcription and regula-
tion that is highly expressed in proliferating cells, as such we
cannot conﬁrm this ﬁnding is not inﬂuenced by higher prolif-
erative activity15 TOP2A overexpression is associated with an
aggressive cancer phenotype and decreased patient
survival,16–18 which makes it an attractive therapeutic target.
Unfortunately, most currently available TOP2A inhibitors
have limited BBB penetration, making them ineffective for
treating brain metastases.19 We did not observe TOP2A
ampliﬁcation in brain metastases, however it is established
that TOP2A protein expression is not secondary to gene
ampliﬁcation, which likely explains this discordance.20
The proteins RRM1, ERCC1 and TS (involved in DNA rep-
lication, repair and chemotherapy resistance) were more fre-
quently expressed in metastases than in primary lesions across
all three tumor pathologies (NSLC, breast cancer and mela-
noma). The DNA repair enzyme ERCC1, which plays a role in
therapeutic resistance to platinum-based chemotherapy,21,22
has not been previously documented to be associated with
Figure 2. Bar graphs of protein expression frequency in brain
metastases (BM), primary lesions and systemic metastases. The
values used to generate this ﬁgure are absolute frequencies of
expression i.e., the number of individual cases showing speciﬁc
protein expression. Signiﬁcant ﬁndings are displayed for (a)
Nonsmall cell lung cancer; (b) breast cancer and (c) melanoma.
Asterisks indicate comparisons that remain statistically signiﬁcant
after correction for multiple comparisons (p < 0.05). Black denotes
brain metastases; blue, primary tumors; and green, systemic
metastases.
Figure 3. Schematic displaying the mutational frequency of cancer-
related genes in primary lesions, brain and systemic metastases. Only
genes with mutational frequency of >10% in at least one subgroup are
shown in the ﬁgure.
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breast cancer brain metastases. Similarly, the DNA synthesis
protein RRM1, which is linked to chemosensitivity to ﬂuoro-
pyrimidine and gemcitabine-based chemotherapy,23 and TS,24
were shown to have increased expression in NSCLC brain
metastases. This expression may be a result of the development
of therapeutic resistance mechanisms to prior therapy or an
intrinsic feature of rare tumor clones in the primary that have
an increased propensity for aggressive behavior, including
metastasis. A recent single institution study reported the geno-
mic analysis of 500 metastatic cancer patients and also
reported a notable incidence of defects in DNA repair in con-
cordance with our ﬁndings.25
Consistent with the literature, we identiﬁed less frequent
expression of hormone receptor expression in breast cancer
brain metastases26–28—although in a much larger patient
cohort and with the novel extension of this to androgen recep-
tor (AR) status. Hormone receptor loss is a known marker of
aggressive disease, negative prognosis and limited treatment
options. It has been suggested that the loss of hormone receptor
expression is due to dedifferentiation of the metastatic tumor29
or the selection of cytogenetically unique clones that have an
enhanced propensity to metastasize to distant sites.30,31 Alterna-
tively, the loss of hormone receptor expression in breast cancer
patients may represent selection bias as a result of treatment.32
Brain metastasis is a late event in hormone receptor-positive
breast cancer. As a breast cancer loses its hormone sensitivity,
it may behave more like triple-negative breast cancer, known to
have a higher rate of brain metastasis and a worse prognosis.33
Because our study did not employ paired primary tumor/
metastasis samples, we cannot exclude the possibility that our
brain metastasis cohort is enriched for triple-negative cases.
Speciﬁc to melanoma brain metastases was the increased
expression of cMET, which is a receptor tyrosine kinase that
binds HGF, thereby leading to the upregulation of oncogenic
signaling cascades. The association of cMET with tumor
progression and brain metastasis has been previously documen-
ted in animal models using cMET knockdown demonstrating
decreased occurrence of brain metastases by 70%.34–36 Therapies
targeting cMET via the use of monoclonal antibodies are in vari-
ous stages of clinical trial testing in multiple cancer histologies,37
but the efﬁcacy of such drugs in the central nervous system is
unclear (NCT02414139, NCT02468661). Another therapeutic
consideration in this setting would be cabozantinib, which is
being evaluated in breast cancer patients with brain metastasis
(NCT02260531).
PD-1 expression was very frequent in both brain metastases
and the primaries of NSCLC and melanoma cancers. The inter-
action between the immune system, tumor and the tumor
microenvironment has been the focus of intense investigation—
speciﬁcally the role of the PD-1/PDL-1 signaling axis,38 The efﬁ-
cacy of PD-1 inhibition (i.e., nivolumab and pembrolizumab) as
a monotherapy or in combination therapy has shown favorable
survival in clinical trials for patients with advanced melanoma
and NSCLC.39–43 However, the role of immune checkpoint
inhibitors in the treatment of CNS cancers, including metastasis,
is currently being deﬁned,44,45 and our current results provide
further support for these agents in this context.
Although most genetic alterations were present at similar fre-
quencies in the brain metastases and the primary tumors, there
were some notable exceptions that were higher in the brain
metastasis. ABL1 mutations and HER2 and EGFR ampliﬁcation
were common in breast cancer brain metastases, consistent with
a prior study of whole-exome sequencing of 86 matched pri-
mary tumor/brain metastasis samples from multiple cancers.46
In previous study, clinically actionable alterations not detected
in matched primary tumors were found in more than 50% of
brain metastases. Our study46 also included matched samples
and tumor pathologies that were not in our data set (e.g., renal
cell carcinoma), some of which were highlighted for their alter-
ations speciﬁc to brain metastases. It is also possible that in our
Table 2. Frequency of gene amplification detected by fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization (CISH) in
brain metastases and in tumors taken from the primary and systemic sites of nonsmall cell lung cancer, breast cancer, and melanoma
NSCLC BREAST CANCER MELANOMA
Gene Brain Primary Systemic Brain Primary Systemic Brain Primary Systemic
EGFR 36.3% 28.0% 34.5% 31.1%2 14.4% 14.2%4 50%1 6.1% 28.9%
(29/80) (438/1,567) (250/724) (14/45) (121/839) (138/970) (4/8) (2/33) (26/90)
TOP2A 0% 5% 1.6% 16.7% 8.5% 6.3%3 0% 0% 0%
(0/14) (9/181) (2/128) (7/42) (112/1,315) (101/1,594) (0/5) (0/1) (0/48)
Her2 5.8% 3.6% 3% 28.8%2 15.3% 13.1%4 0% 0% 0%
(10/171) (79/2,207) (36/1,204) (23/80) (430/2,808) (361/2,767) (0/41) (0/205) (0/247)
cMET 6.4% 4% 5.2% 5.6% 1.1% 0.7% 8.6%1 0.6% 3.5%
(8/125) (61/1,517) (47/906) (1/18) (11/1,027) (7/987) (3/35) (1/168) (8/230)
NSLC, nonsmall cell lung cancer.
1Bivariate analysis p < 0.05 (brain metastases relative to primary).
2Corrected for multiple testing p < 0.05 (brain metastases relative to primary).
3Bivariate analysis p < 0.05 (systemic metastases relative to brain metastases).
4Corrected for multiple testing p < 0.05 (systemic metastases relative to brain metastases)
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analysis, we were not powered to detect mutations present at a
low frequency (subclonal events). Yet, our sample size was very
large, which allowed for rigorous statistical analysis. Comparing
the ﬁndings of the current study to smaller cohorts of published
samples is challenging as the majority of studies focus on muta-
tional changes/alterations in oncogenic signaling pathways while
the major ﬁndings in our study focus on differential protein
expression.47,48 For example, a study comparing marker proﬁles
of the 43 tumors that had evaluable material from matched sets
of primary breast cancer and brain metastases showed no statis-
tically signiﬁcant difference between the primary and metastatic
breast carcinomas for any markers.49 However, these authors
did not assess for several of the markers evaluated in our study,
which were found to be signiﬁcantly higher in breast cancer
brain metastases (i.e. TOP2A, TOPO1, ERCC1). An additional
study by Thompson et al. compared 41 matched breast and
brain metastases. These authors reported signiﬁcant differences
in p27kip1 and cyclin D1 expression between brain and primary
lesions, however, they also did not assess the expression of the
markers listed above.50
Although our study is strengthened by its large sample size
and wide array of markers analyzed, it has limitations. To col-
lect such a large volume of data, a commercial database was
utilized and clinical annotation is not available, including prior
treatment regimens. Hence, we cannot account for the impact
of treatment-related changes on the patterns of expression in
the brain metastasis samples. Furthermore, this analysis does
not clarify whether the differentially expressed proteins are the
etiology for the development of brain metastasis or are a reﬂec-
tion of the unique brain microenvironment, which would be
informative for preventive strategies. Additionally, we cannot
exclude the possibility that tumors from different sites may
represent variations in molecular subtype or different stages of
the disease. Ideally matched samples would better resolve these
questions; however, matched samples collected from multiple
centers worldwide from a cohort size of this magnitude is not
feasible and is a major challenge even at a single institution.25
Yet, this is the largest data set with genomic/molecular charac-
terization of brain metastases to date.
In conclusion, despite these limitations, we found enriched
expression of a number of novel markers associated with
DNA synthesis, replication and repair in brain metastases
compared with primary cancer specimens. This trend
occurred across tumor histologies, supporting the prioritiza-
tion of therapies that target these pathways. Although several
of the therapeutic target candidates are not brain metastasis-
speciﬁc genes, overexpressed proteins, or ampliﬁed genes, this
data informs which targets would be suitable for therapeutic
purposes during advanced stage metastasis, with the inclusion
of brain metastasis patients.
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